时间标签：数据日期 2026-11-05 · 生成时间 2026-11-05 05:30（Asia/Shanghai）｜ 检索窗口 PubMed edat 2026/11/02 – 2026/11/06 ｜ 情报发生日期 2026-11-05
研究问题
（原文未给出可直接抽取的对应表述）
方法
We establish a mapping matrix (Figure 1) that directly couples each technological advance to multi-layered stroke research demands, stratified into four hierarchical levels: (1) basic pathology—faithful recapitulation of ischemic–hypoxic and excitotoxic core events; (2) tissue microenvironment—multi-cellular vascular–immune–neural interactions; (3) remote network—secondary damage in distant brain regions; (4) translational utility—perfusion, drug administration, and transplantation.；Taking these four demand layers as the vertical axis and organoid engineering strategies/iterations—static 3D → vascularized/regionalized → chip-integrated dynamic → multi-organ coupling—as the horizontal axis, we systematically examine progress and gaps at each intersection.；We searched PubMed, Web of Science, and Scopus through August 2026 using combinations of the following terms: brain organoids, cerebral organoids, assembloids, organoid-on-a-chip, microfluidics, stroke, ischemic stroke, hemorrhagic stroke, oxygen–glucose deprivation, OGD/R, neuroinflammation, PANoptosis, ferroptosis, SRGAP2C, electrophysiology, multi-electrode array, and transplantation.
核心结论
NMDA receptor antagonists showed robust rodent efficacy yet collectively failed in human trials—not merely because of GluN2A/GluN2B ratio differences, but because human excitotoxic signaling depends more heavily on scaffolding complexes such as PSD-95/nNOS, which rodent models inadequately capture (Ma et al., 2026).；Ratings were assigned by author consensus based on these criteria and the available literature. “Low” indicates limited, indirect, or largely conceptual evidence; “Moderate” indicates partial capability with substantial limitations; and “High” indicates that the platform has demonstrated relatively strong capability in addressing the corresponding demand under at least some validated conditions, while not implying complete biological recapitulation.；Ratings were based on three predefined considerations: direct experimental evidence supporting the relevant capability, reproducibility across studies or experimental settings, and functional alignment between platform characteristics and stroke research requirements. “Low” indicates limited or indirect evidence; “Moderate” indicates partial capability with substantial limitations; and “High” indicates that a platform has demonstrated relatively strong capability under specific validated conditions, without implying complete recapitulation of physiological complexity.
局限
1Introduction1.1Systemic limitations of current stroke modelsOver the past 2 decades, more than 1,000 neuroprotective strategies validated in animal models have largely failed in clinical trials, with a translational success rate of less than 5%.；Standardized preclinical guidelines have long emphasized the need to test agents in multiple species, ages, and comorbid conditions—standards rarely met in practice (Dirnagl and Endres, 2014; Fisher et al., 2009).Second, 2D culture limitations.；Recent advances in self-assembling brain organoids, vascularized organoids, and organoid–microfluidic integrated systems have enabled more complex reconstruction of human neurovascular features in vitro, providing additional tools to investigate limitations of conventional models.
对本项目的价值
中高价值：属「干细胞 / 部分重编程与再生」方向；干细胞 / 再生 / 重编程栏目可用作本项目文献库与综述素材。 ｜ 价值分 3.4/5（★★★☆☆）
全文来源
PubMed PMC JATS（正文 48,555 字符，题名指纹 0.69，已过 PubMed PMCID 官方关联 + 题名指纹 + 正文长度归属校验）
原文题录
- 中文题名：绘制技术-需求界面：脑类器官进化如何重塑卒中的转化图景
- 英文标题：Mapping the technology-demand interface: how brain organoid evolution is reshaping the translational landscape of stroke.
- 期刊与标识：Frontiers in cell and developmental biology · PMID 42978846 · DOI 10.3389/fcell.2026.1983701 · PMC PMC13728352